LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.22 2.52

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.1400000000000001

Max

1.28

Põhinäitajad
By Trading Economics
Sissetulek	-124K -32M
Müük	-372K 1.4M
Aktsiakasum	-0.27
Kasumimarginaal	-2,364.792
Töötajad	161
EBITDA	-13M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+99.12% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-40M 134M
Eelmine avamishind	-1.3
Eelmine sulgemishind	1.22

Uudiste sentiment

By Acuity

41%

59%

139 / 350 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. märts 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Infosys Agrees to Acquire Stratus

25. märts 2026, 23:58 UTC

Tulu

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25. märts 2026, 23:58 UTC

Tulu

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25. märts 2026, 23:57 UTC

Tulu

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25. märts 2026, 23:57 UTC

Tulu

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25. märts 2026, 23:56 UTC

Tulu

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25. märts 2026, 23:56 UTC

Tulu

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25. märts 2026, 23:41 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25. märts 2026, 23:41 UTC

Tulu

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25. märts 2026, 23:34 UTC

Market Talk

Uudisväärsed sündmused

Gold Declines on Possible Technical Correction -- Market Talk

25. märts 2026, 22:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. märts 2026, 22:08 UTC

Market Talk

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25. märts 2026, 21:58 UTC

Market Talk

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25. märts 2026, 21:37 UTC

Market Talk

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25. märts 2026, 21:14 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25. märts 2026, 21:13 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25. märts 2026, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

25. märts 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

25. märts 2026, 20:33 UTC

Omandamised, ülevõtmised, äriostud

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25. märts 2026, 20:31 UTC

Tulu

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

99.12% tõus

12 kuu keskmine prognoos

Keskmine 2.25 USD 99.12%

Kõrge 2.5 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

139 / 350 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.